E K Rowinsky
Overview
Explore the profile of E K Rowinsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
159
Citations
4311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mita A, Papadopoulos K, de Jonge M, Schwartz G, Verweij J, Mita M, et al.
Br J Cancer
. 2011 Sep;
105(7):938-44.
PMID: 21878940
Background: To evaluate the anticancer activity of erlotinib in patients with previously treated, advanced non-small cell lung cancer (NSCLC) whose dose is increased to that associated with a maximal level...
2.
Baker J, Dutta D, WATSON D, Maddala T, Munneke B, Shak S, et al.
Br J Cancer
. 2011 Jan;
104(3):488-95.
PMID: 21206494
Background: Although it is accepted that metastatic colorectal cancers (mCRCs) that carry activating mutations in KRAS are unresponsive to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, a significant fraction of...
3.
Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, et al.
Ann Oncol
. 2010 Jul;
22(1):104-109.
PMID: 20603437
Purpose: recent studies have found that KRAS mutations predict resistance to monoclonal antibodies targeting the epidermal growth factor receptor in metastatic colorectal cancer (mCRC). A polymorphism in a let-7 microRNA...
4.
Calvo E, Malik S, Siu L, Baillargeon G, Irish J, Chin S, et al.
Ann Oncol
. 2007 Feb;
18(4):761-7.
PMID: 17317676
Background: The purpose of the study was to evaluate the effects of erlotinib on epidermal growth factor receptor (EGFR)-related signaling elements in tumor and skin from patients with advanced squamous...
5.
Mita M, Ochoa L, Rowinsky E, Kuhn J, Schwartz G, Hammond L, et al.
Ann Oncol
. 2005 Dec;
17(2):313-21.
PMID: 16322117
Purpose: To assess the feasibility and antitumor activity of oblimersen sodium, an antisense oligonucleotide directed to the Bcl-2 mRNA, combined with irinotecan in patients with advanced colorectal carcinoma, characterize the...
6.
de Bono J, Rha S, Stephenson J, Schultes B, Monroe P, Eckhardt G, et al.
Ann Oncol
. 2004 Nov;
15(12):1825-33.
PMID: 15550589
Background: BrevaRex mAb-AR20.5 is a murine anti-MUC1 monoclonal antibody generated to induce MUC1 antigen-specific immune responses through the formation of immune complexes with circulating MUC1 and/or MUC1-expressing tumor cells that...
7.
SCHWARTZ G, Patnaik A, Hammond L, Rizzo J, Berg K, Von Hoff D, et al.
Ann Oncol
. 2003 Apr;
14(5):775-82.
PMID: 12702533
Background: The aim of this study was to assess the feasibility of administering bizelesin, a cyclopropylpyrroloindole with extraordinarily high potency as a bifunctional DNA-damaging agent and selectivity for specific AT-rich...
8.
Tolcher A, Gerson S, Denis L, Geyer C, Hammond L, Patnaik A, et al.
Br J Cancer
. 2003 Apr;
88(7):1004-11.
PMID: 12671695
Temozolomide, an oral DNA methylator that inactivates the DNA repair enzyme O(6)-alkylguanine-DNA alkyltransferase (AGAT), has demonstrated anticancer activity on protracted schedules. Protracted schedules may lead to an 'autoenhancement' of temozolomide's...
9.
Britten C, Rowinsky E, Soignet S, Patnaik A, Yao S, Deutsch P, et al.
Clin Cancer Res
. 2001 Dec;
7(12):3894-903.
PMID: 11751480
This Phase I study was performed to assess the feasibility of administering L-778,123, a peptidomimetic farnesyl protein transferase (FPTase) inhibitor, as a continuous i.v. infusion for 7 days every 3...
10.
OReilly S, Hartman N, Bowling K, Rowinsky E, Donehower R, Collins J, et al.
Cancer Chemother Pharmacol
. 2001 Oct;
48(3):223-8.
PMID: 11592344
Purpose: Oral administration of penclomedine was investigated based on preclinical studies indicating that an oral schedule of penclomedine treatment may prevent the neurotoxicity observed in phase I studies of an...